What is the difference between the previous and updated data presented?

The updated data has a later cutoff date (May 25, 2018 vs. March 28, 2018) and longer patient follow-up (minimum 24 weeks vs. 18 weeks). This extended observation period led to higher observed response rates: 85.7% ORR and 61.4% CR in the updated data, compared to 72.9% ORR and 50.0% CR in the prior data.

Does the update indicate that the treatment effect is durable?

Yes, the fact that the median duration of response has not been reached in either the previous or updated data sets suggests that the responses observed with tislelizumab are potentially durable, which is a crucial factor for long-term patient benefit and commercial success.

Are these final results for the Phase 2 trial?

No, these are described as 'additional preliminary topline results.' This means the trial is ongoing, and these are not the final efficacy data. Further updates and final results are expected as the trial continues.

ONC/BEIGF 8-K SEC Disclosure

Q: What is the significance of the updated Phase 2 trial results for tislelizumab?

The updated results show a notable improvement in efficacy, with higher overall and complete response rates for tislelizumab in patients with relapsed/refractory classical Hodgkin’s lymphoma. This strengthens the potential of tislelizumab as a treatment option and is a positive development for Beigene.

Summary

This 8-K filing from Beigene, Ltd. (ONC) provides updated, positive preliminary topline results from its pivotal Phase 2 trial of tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with relapsed/refractory classical Hodgkin’s lymphoma. The additional data, with a later cutoff date of May 25, 2018, demonstrates an improved overall response rate (ORR) of 85.7% and a complete response rate (CR) of 61.4%, compared to the previously reported figures of 72.9% ORR and 50.0% CR from the March 28, 2018 data cutoff. This indicates a potentially stronger efficacy profile for tislelizumab with longer follow-up. The extended follow-up period of at least 24 weeks (median of 7.85 months) also suggests durability, as the median duration of response had not yet been reached in either data set. These encouraging results are crucial for investors as they bolster the potential of tislelizumab, a key asset for Beigene, and could positively impact future regulatory submissions and commercial prospects in China.

Key Highlights

1Beigene released updated, positive topline results from its Phase 2 trial of tislelizumab in relapsed/refractory classical Hodgkin’s lymphoma patients in China.
2The new data, with a May 25, 2018 cutoff, shows an improved Overall Response Rate (ORR) of 85.7% and a Complete Response Rate (CR) of 61.4%.
3These improved rates represent an increase from previously reported data (72.9% ORR, 50.0% CR) with a March 28, 2018 cutoff.
4The updated trial data includes a minimum of 24 weeks of patient follow-up, with a median follow-up of 7.85 months.
5The median duration of response has not been reached in either data set, suggesting potential durability of treatment effect.
6Tislelizumab is Beigene's investigational anti-PD-1 antibody, a significant asset for the company.

BeOne Medicines Ltd. 8-K Report, Corporate Update (Jul 30, 2018)

Summary

Key Highlights

Frequently Asked Questions